ArticleBMC infectious diseases2026
Drug resistance mechanisms and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in pulmonary infections.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAs a highly drug-resistant nosocomial pathogen, Carbapenem-resistant Klebsiella pneumoniae (CRKP) often causes pulmonary infections with high mortality rates, and deciphering its molecular characteristics and drug resistance mechanisms is crucial for rational clinical drug use.
objectiveThis study aimed to investigate the drug resistance mechanisms and molecular epidemiological characteristics of pulmonary infections caused by CRKP. The findings intend to provide a scientific basis for optimizing antibiotic use and developing effective clinical prevention and control measures.
methodsNon-repetitive CRKP strains isolated from bronchoalveolar lavage fluid and qualified sputum samples of hospitalized patients at a Class A tertiary hospital in Yunnan Province from April 2020 to June 2024 were collected. The VITEK 2 Compact automatic bacterial identification system, along with the Kirby-Bauer disk diffusion method and broth microdilution method, were employed to conduct antimicrobial susceptibility testing and assess resistance phenotypes. Additionally, whole-genome sequencing (WGS) technology was employed to analyze resistance genes, virulence genes, and multi-locus sequence typing (MLST), and a phylogenetic tree was constructed.
resultsA total of 70 non-repetitive CRKP isolates were collected. The strains exhibited high resistance to most antimicrobial agents but remained sensitive to tigecycline, polymyxin B, and ceftazidime/avibactam. Various antibiotic resistance genes were identified, with blaKPC−2 (62.9%) being the predominant carbapenemase gene, followed by blaOXA−232 (22.9%). High detection rates were observed for virulence genes, including type I pili (fimCDFGHI), type III pili (mrkABCDFHJ), and iron-uptake system genes (iroN, iutA, fep, ent, fes). Six sequence types were identified, with ST11 (61.4%) being the most prevalent.
conclusionCRKP strains isolated from pulmonary infections displayed extensive multidrug resistance, primarily attributed to the ST11 lineage and blaKPC−2 as the main carbapenemase gene. The frequent detection of multiple key virulence factors underscores the importance of precise antibacterial treatment and vigilant molecular epidemiological surveillance. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.